Translator Disclaimer
13 February 2017 Tracking delivery of a drug surrogate in the porcine heart using photoacoustic imaging and spectroscopy
Author Affiliations +
Abstract
Although the drug-eluting stent (DES) has dramatically reduced the rate of coronary restenosis, it still occurs in up to 20% of patients with a DES. Monitoring drug delivery could be one way to decrease restenosis rates. We demonstrate real-time photoacoustic imaging and spectroscopy (PAIS) using a wavelength-tunable visible laser and clinical ultrasound scanner to track cardiac drug delivery. The photoacoustic signal was initially calibrated using porcine myocardial samples soaked with a known concentration of a drug surrogate (DiI). Next, an in situ coronary artery was perfused with DiI for 20 min and imaged to monitor dye transport in the tissue. Finally, a partially DiI-coated stent was inserted into the porcine brachiocephalic trunk for imaging. The photoacoustic signal was proportional to the DiI concentration between 2.4 and 120  μg/ml, and the dye was detected over 1.5 mm from the targeted coronary vessel. Photoacoustic imaging was also able to differentiate the DiI-coated portion of the stent from the uncoated region. These results suggest that PAIS can track drug delivery to cardiac tissue and detect drugs loaded onto a stent with sub-mm precision. Future work using PAIS may help improve DES design and reduce the probability of restenosis.

1.

Introduction

Percutaneous coronary intervention is performed in almost 0.5 million cases each year in the United States and involves placement of a stent with a balloon that is inflated in the diseased coronary artery.1 This procedure has improved in recent years with the advent of the drug-eluting stent (DES). There is still concern about failure rates from vessel renarrowing, restenosis, with cases occurring in up to 20% of patients.15 We hypothesize that these failures would be minimized by evaluating in situ coronary artery drug delivery.614

Restenosis was minimized by improving drug retention and transport in the coronary artery. Drug delivery to the tunica media has reduced or prevented migration and proliferation of vascular smooth muscle cells that cause restenosis.15 Drug diffusion and retention has also increased by modifying the drug’s physiochemical properties. For example, the 42’ hydroxyl group on rapamycin (a common drug on DES) has been replaced with a tetrazole ring (zotarolimus) that improves hydrophobicity, promoting retention and prolonged release, while minimizing washout.14,16

The design and performance of a DES may be enhanced by monitoring or visualizing drug delivery to the coronary artery. This is supported by our findings that demonstrate drug transport and mechanical properties of the porcine coronary arteries vary as a function of vessel and location.68 However, currently, there is no ideal imaging modality to monitor and quantify drug delivery to the coronary artery with sub-mm precision.

Although noninvasive imaging modalities, such as magnetic resonance imaging, computed tomography, and ultrasound (US), are capable of anatomical and functional imaging of the heart and coronary artery, they typically lack sufficient contrast to identify and track pharmacologic compounds in the vasculature and myocardium. Optical imaging techniques have drawbacks as well. Fluorescence microscopy and histology require toxic dyes and tissue destruction. Multiphoton confocal microscopy has limited depth penetration of less than 1 mm.6,17,18 As a result, there are drawbacks to popular techniques used for tracking drug delivery from a DES in an intact heart. On the other hand, photoacoustic (PA) imaging and spectroscopy combined with pulse echo (PE) US potentially overcomes these limitations by offering real-time volumetric imaging with sub-mm resolution deep into tissue. With the benefit of spectroscopy, photoacoustic imaging and spectroscopy (PAIS) also provides high contrast and specificity for detecting and tracking optically absorbing compounds in the vascular tissue and myocardium. These attributes are not only favorable for testing and improving the performance of a DES, but the technology is potentially translatable for in vivo imaging in large animals and humans.

PA imaging is based on the PA effect, the generation of acoustic waves caused by the absorption of a short pulse of light, transient heating, and thermoelastic expansion. These acoustic waves are detected to form an US image with contrast proportional to the absorption of light, which depends on the optical wavelength. The distribution and relative concentration of optically absorbing drugs and contrast agents can also be estimated with high specificity by sweeping the optical wavelengths. In this study, we propose PAIS as a method to track transport of a drug surrogate in the porcine myocardium and coronary arteries. We also demonstrate imaging of a laser-sintered DES coated with a drug surrogate (also a PA contrast agent) and track its position in the intact porcine brachiocephalic trunk.

2.

Materials and Methods

Optical and US setup: a wavelength-tunable laser (Surelite-II OPO, Continuum, 5-ns pulses, 20-Hz pulse repetition rate, and 20  mJ/pulse) operating between 410 and 670 nm was coupled into a 1.6-mm-diameter multimode optical fiber (CeramOptec) that connected to a “photoacoustic enabling device” (PED). Specifically, the PED held both the optical components and linear US array (Zonare L10-5, 7.1-MHz center frequency, and 5-MHz bandwidth) for coregistered PE and PA imaging, which has been previously described.19,20 Furthermore, the PED allowed for coalignment between the optical illumination and plane of US detection. Briefly, light from the fiber passed through a cylindrical lens to provide line illumination at the surface of the tissue. The backscattered PA waves were reflected by an inline acoustic reflector before being detected by the linear array and recorded in real-time by a clinical US scanner (zOneUltra, Zonare Medical Systems). The PED was filled with water for acoustic coupling. Raw frame data (amplitude and phase) were transferred from the scanner to a personal computer running MATLAB™ for sum-delay beamforming and postsignal processing. The axial and lateral resolutions of the PA imaging system were 300 and 400  μm, respectively.19 The slice thickness was 2  mm. The fluence on the surface of the heart was 10  mJ/cm2 and below the American National Standards Institute safety limit of 20  mJ/cm2 per pulse light at visible wavelengths.21

Drug surrogate: 1,1’-dioctadecyl-3,3,3’,3’-tertramethyllindocarbocyanine perchlorate (DiI) was selected for PA imaging due to its weight match to rapamycin, hydrophobic nature, cost, and favorable absorbance spectrum at visible wavelengths [Fig. 1(b)].6 DiI was acquired from Invitrogen (Carlsbad, California).

Fig. 1

PA imaging setup and optical properties of DiI. (a) Nd: YAG laser was tripled to 355 nm to pump an optical parametric oscillator and produce tunable 5 ns pulses between 410 and 670 nm. Laser light was coupled into a 1.6-mm-diameter multimode glass fiber. The fiber connected to a PA flashlight adapter, including an optical assembly with a cylindrical lens to produce a line pattern on the heart.20 The adapter also contained a water-filled cavity for acoustic coupling and an acoustic reflector, which ensures coalignment of the light with the plane of US detection. A clinical US scanner (zOneUltra, Zonare Medical Systems) and 7-MHz linear array (L10-5) recorded the raw acoustic signals (phase and amplitude) for US and PA imaging. The frame data were transferred to a PC for beamforming, postprocessing, and analysis in MATLAB™. (b) Optical absorption spectrum of DiI as measured with a photospectrometer (Ocean Optics, USB4000).

JBO_22_4_041016_f001.png

2.1.

Image Processing and PA Signal Decomposition (Unmixing)

The primary optical absorbers at visible wavelengths in this study were the myocardium and DiI, which were separated by spectral decomposition. The PA signal is calculated as

Eq. (1)

PA=T*φ*μ,
where PA is the PA signal in MPa, T is the dimensionless Grüneisen constant that converts optical energy into acoustic pressure, φ is the laser fluence J/cm2, and μ is the total absorption coefficient in cm1.22 Total tissue absorption equals the sum of the signals obtained, which is described as

Eq. (2)

μtotal=m=1Mcm*μm,
where cm is the concentration of the m’th absorber, μm is the absorption coefficient of the m’th absorber, and M is the number of tissue absorbers. The fraction of sample absorbers is written in matrix notation as

Eq. (3)

Ac¯=b¯,
with A an M×N matrix containing the absorption coefficient of M absorbers at N wavelengths. c¯ is a 1×M vector containing a fractional distribution of M agents. b¯ is a 1×N vector of a normalized PA signal over each wavelength.9 The least squares of the residuals is used to solve for c^

Eq. (4)

c^=(AT*A)1*AT*b¯,
c^ is a signal estimation of a specific absorber based on least squares. This technique separates DiI from the myocardium and other possible absorbers such as hemoglobin.

2.2.

Photoacoustic Imaging Experiments

2.2.1.

Porcine cardiac tissue

All tissue obtained in this study was approved through the University of Arizona Institutional Animal Care and Use Committee. Adult porcine hearts (n=5) were acquired from the University of Arizona Food Products and Safety Laboratory and maintained at 4°C for up to 24 h until imaging.

2.2.2.

Validation and calibration in excised myocardium

A porcine left ventricle was cut into seven rectangular sections (1×1×0.5  cm). Samples were soaked in DiI for 24 h at different concentrations (0, 2.4, 4.8, 9.6, 38.4, 76.8, and 120  μg/ml) and embedded in agarose gel. Volumetric PA and US images were collected by scanning the linear array along the elevational axis with 100  μm increments. The average PA signal was calculated over the region of interest (ROI), which was determined from the coregistered B mode US image and excluded the tissue boundary. A calibration curve was generated by plotting the average PA signal versus the DiI concentration.

2.2.3.

In situ porcine heart imaging

Three porcine hearts were cut proximal and distal to the coronary artery, and a cannula was inserted into the left anterior descending coronary artery (LADCA), which was initially flushed with water using a syringe pump (KD Scientific KDS230 KDS 230 Multi-Syringe Pump). Standard US helped identify the vessel location, size, and structure. Cross sectional PA images were taken from 430 to 670 nm (10 nm increments). The porcine LADCA was perfused with 2.4  μg/ml and maintained for 20 min, followed by imaging, flushing with water, and reimaging with PE and PA. The process was repeated at incrementally higher concentrations (i.e., 12 and 60  μg/ml). The relative contribution of DiI at each pixel was determined from spectral decomposition. The distribution of DiI was also used to calculate coronary artery diffusion area and distance. Diffusion area was calculated by subtracting the background from the DiI signal and setting a threshold value. The total number of pixels with DiI was multiplied by the pixel size (0.05  mm×0.05  mm) to determine the diffusion area. The center of the LADCA was determined from the PE US image, and the diffusion distance was calculated by extending a line from the LADCA center point radially outward. Continuous pixel values along the line greater than background was used to calculate diffusion distance.

2.2.4.

Imaging of DiI-coated stent

A cobalt chromium stent with a sinusoidal pattern was designed in Solidworks® and fabricated by Proto Labs®. Half of the stent was dipped into DiI/PCL (60  μg/ml DiI and PCL) solution and dried for 20 min; this process was repeated three times. A coating of polydimethylsiloxane (PDMS) was also added to prevent short-term elution. The uncoated region served as a control to compare to the coated region. The stent was initially imaged in water and, later, inserted into the brachiocephalic trunk for both PA and PE imaging.

3.

Results

3.1.

Validation and Calibration in Excised Myocardium

Images of four of the seven myocardial samples are displayed in Fig. 2. Wavelengths of 550 and 660 nm represented the local maximum and minimum for DiI absorption in the visible range. Whereas at 550 nm, the PA image was dominated by DiI absorption, at 660 nm the image was dominated by the intrinsic absorption of the myocardium. In general, the PA signal intensity increased linearly with concentration. The final column represents the DiI concentration after unmixing the PA signal at all the wavelengths.

Fig. 2

US and PA imaging of porcine myocardial samples stained with DiI. Each row represents a sample stained with a different concentration of DiI (0, 38.4, 76.8, and 120  μg/ml). (a) Cross-sectional PE US images of samples embedded in Agarose™. Samples are outlined in green. (b) Corresponding PA signal at 550 nm (near peak of DiI absorption). (c) PA signal at 660 nm (low DiI absorption). (d) Relative concentration of DiI after spectral decomposition. Green scale bar represents 2 mm.

JBO_22_4_041016_f002.png

These data were used to generate a calibration curve for DiI in the excised myocardium. The average PA signal (over the ROI) was plotted against the prepared DiI concentration (Fig. 3). The axes are displayed in octaves to match the distribution of prepared DiI concentrations.

Fig. 3

PA calibration curve for DiI. The pixel values over the ROI were averaged and plotted against the prepared concentration of DiI for each sample. The equation for the best fit line (dashed red) and R2 value are also indicated. All concentration values are in μg/ml. Based on the PA signal without DiI (blue-dashed line), the sensitivity of PA for detecting the dye in the samples was 2  μg/ml.

JBO_22_4_041016_f003.png

Figure 3 indicates a strong linear relationship spanning almost eight octaves between the DiI sample concentration and the amplitude of the PA signal. In addition, minute concentrations of DiI (<2.4  μg/ml) could be detected at high spatial resolution (<300  μm) deep in tissue (>5  mm). These favorable attributes of PA imaging were extended to study transport in the porcine coronary artery and myocardium.

3.2.

Imaging of the Porcine Heart (In Situ)

DiI at 2.4  μg/ml was perfused into the LADCA for 15 s (see Fig. 4). The PA signal at 550 nm near branching vessels increased linearly during the perfusion, demonstrating real-time capabilities of PA imaging for tracking drug transport and diffusion.

Fig. 4

Increase in PA signal near LADCA during DiI perfusion. (a) Cross sectional PE image of an ex vivo porcine heart. (b) Coregistered PA image at 550 nm during infusion of 2.4  μg/ml DiI. Vessel pressure was maintained at 70 mm Hg. (c) Average PA signal over time inside dashed green box during infusion of DiI. The PA signal increase is observed in myocardial tissue adjacent to the coronary (CA) vessel. The scale bar denotes 2 mm.

JBO_22_4_041016_f004.png

Estimates of DiI diffusion in the porcine heart are presented in Fig. 5. The PA spectrum was dominated by absorption of the myocardium except at regions with high DiI. Areas of DiI diffusion for 2.4, 12, and 60  μg/ml were calculated at 1.30, 1.75, and 3.30  mm2, respectively. Therefore, an increase in DiI concentration led to an increase in diffusion area. These results demonstrated that PA imaging can track transport of DiI, a drug surrogate.

Fig. 5

Estimation of DiI diffusion in the heart near the LADCA. (a) Cross sectional PE US image over LADCA. (b) Coregistered PA image at 550 nm with a dynamic range of 40 dB. The PA spectra over regions of interest marked with “X” are displayed in (c). Brown and blue regions are similar to the known absorption spectra of the myocardium and DiI, respectively. (d) Coregistered PE (gray) and unmixed PA signal for 60  μg/ml DiI concentration (following flush). Green box identifies the ROI for cumulative diffusion analysis. (e) PA images over ROI (green box) for DiI concentration of 0 (100% water), 2.4, 12, and 60  μg/ml. (f) Diffusion area for each concentration based on PA signal over background. Scale bar is 2 mm.

JBO_22_4_041016_f005.png

In addition to diffusion area, we also calculated the diffusion distance from the center of LADCA, which depended on the concentration (see Fig. 6). DiI diffused an average of 0.95±0.37  mm, ranging from 0.6 to 1.5 mm [Fig. 6(c)]. These results suggest that PA imaging can track transport several millimeters from the coronary into the myocardium.

Fig. 6

Diffusion distance from LADCA. (a) Cross sectional US image of the LADCA in the porcine heart. (b) Overlay of PE US (gray) and PA (hot) images. Scale bar=2  mm. (c) Calculation of diffusion distance from LADCA based on signal above threshold noise inside dashed box in (b). Diffusion distance for this example ranged from 0.6 to 1.5 mm. Scale bar=1  mm.

JBO_22_4_041016_f006.png

3.3.

Ultrasound and Photoacoustic Imaging of a DiI-Coated Stent

A cardiovascular stent was fabricated to test if PA imaging could detect DiI coated on a stent placed inside a blood vessel. Images of the DiI-coated cardiovascular stent are presented in Fig. 7. PA imaging was able to differentiate the coated versus uncoated region in water and in the brachiocephalic trunk [Figs. 7(d) and 7(f), respectively]. These results demonstrated that PA imaging was able to detect DiI on a stent placed inside a large blood vessel.

Fig. 7

PE and PA imaging of DiI-coated cardiovascular stent. (a) Zoomed-in photograph of sinusoidal pattern of stent; (b) top view PE US image of stent at 7.1 MHz. (c) Top view photograph of stent with DiI/PCL+PDMS coating on top half. (d and e) Coregistered PE US (gray) and PA (hot) at 550 nm image (d=long view, e=cross view) of stent in water with coating on top half. (f) Coregistered US and unmixed PA signal of stent implanted in the brachiocephalic trunk. Scale bar=2  mm. Green box highlights the stent in the blood vessel.

JBO_22_4_041016_f007.png

4.

Discussion

Our results demonstrated that PAIS is a nondestructive method that tracks drug delivery in the porcine vasculature while providing excellent contrast, depth, and resolution. PAIS was able to quantify the distribution of a drug surrogate at concentrations from 2.4 to 120  μg/ml. Perfusion of DiI into the coronary artery increased the PA signal in the surrounding tissue greater than 1.5 mm away from the targeted vessel. PAIS was also able to differentiate the brachiocephalic trunk from the coated and uncoated regions of a stent. Our results suggest that PAIS may be a valuable tool for tracking drug delivery to a specific vessel and provide feedback on drugs loaded onto a DES. In this regard, PAIS may help improve the design of a DES, increase drug retention and delivery to the coronaries arteries, and reduce in-stent restenosis.

Our approach has not only demonstrated that PAIS may be a useful tool for assessing drug delivery in vitro but could also be used in preclinical animal models of vascular disease. For example, a porcine thoracic window to the coronary artery could provide time course information about in vivo drug delivery.23 Specifically, DES polymer degradation and therapeutic drug transport could be monitored over time in the same animal, thus minimizing the number of animals used in preclinical studies. Our results further suggest that the PA signal from the stent and surrounding tissues could be used to estimate drug concentrations thus providing real-time feedback for improving DES designs.

To visualize drug delivery, this study implemented a drug surrogate with a peak absorption near 550 nm. At this wavelength, penetration depth in cardiac tissue is about 5  mm due to overlap in intrinsic background absorption (e.g., hemoglobin). However, if the drug surrogate is exchanged for a near-infrared (NIR) absorber, PAIS should be able to track drug delivery even deeper (>10  mm) into tissue with less interference from background absorption.23 In this case, it may be possible to use fewer wavelengths for spectral decomposition, thereby simplifying the imaging procedure and scan time. In general, most restenosis drugs absorb in the ultraviolet range, which limits penetration depth.24,25 Therefore, it could be desirable to conjugate a small-molecule dye onto the drug to track delivery using PAIS. For example, the 42’ hydroxyl group on rapamycin has shown great promise for conjugation of an optically absorbing dye. One group has successfully attached 7-bromo-4-nitrobenzofurazan, a visible spectrum dye, onto rapamycin.26 Conjugating rapamycin with a visible or NIR absorber would facilitate PAIS for quantifying drug delivery to the coronary artery.

In order to track drug delivery, there are many confounding factors that affect the PA signal in the heart: dye concentration, laser fluence, sample geometry, dye distribution, background absorption, and photobleaching. To reduce effects of pulse-to-pulse variations of the laser, we averaged the signal at each location over several pulses. Photobleaching of the dye was also kept to a minimum by only exposing the samples to light while recording data (typically less than 10 pulses at each location). To reduce effects of the geometry on the PA signal during the calibration experiment, each sample was cut to a similar size and shape and placed in the agarose gel at the same depth. The ROIs were chosen inside the sample to reduce boundary effects of the PA signal. Finally, dye variations inside each sample were reduced by soaking the samples for 24 h in the dye. A similar protocol was employed by Keyes et al. prior to PA imaging in porcine LADCA samples.6 In that study, it was assumed that 24 h was sufficient for saturation of the dye in the tissue.

There were two other primary limitations in this study. First, the spatial resolution of 300  μm was limited by the 5-MHz bandwidth of the US transducer. A higher frequency US probe (e.g., >50  MHz) could be incorporated into our system to improve the resolution to less than 50  μm, which would be sufficient to track diffusion through layers of the coronary wall.27 Another limitation was the inability to directly apply our setup to image the heart in vivo. Although transthoracic PA imaging is possible, penetration would be limited to about 2 cm. In this case, intravascular US/PA (PA-IVUS) would be the most practical solution for in vivo cardiac imaging of a DES. Currently, PA-IVUS has been used to track the position of a stent and detect vulnerable plaque in animal models.2831 Such probes are being developed and tested by other groups with the ultimate goal of clinical translation.29,3235

In summary, this study demonstrated that PA imaging offers excellent spatial resolution, penetration, and contrast for tracking transport of a drug surrogate in the porcine vasculature. PAIS also improves the specificity for estimating drug concentrations by separating the signal from intrinsic background absorbers in cardiac tissue. In vivo PA imaging of drug retention and delivery in the coronaries could help improve the design and performance of a DES and reduce the probability of restenosis during interventional treatment of CHD.

Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

Acknowledgments

This research was funded by the National Science Foundation GK-12 fellowship and the Technology Research Initiative Fund (TRIF). Dr. Russell S. Witte is an inventor on a patent (ultrasonic/photoacoustic imaging devices and methods, US20130039147), which has a licensing arrangement between the University of Arizona and Zonare Medical Systems.

References

1. 

M. Writing Group et al., “Heart disease and stroke statistics-2016 update: a report from the American Heart Association,” Circulation, 133 (4), e38 –e360 (2016). http://dx.doi.org/10.1161/CIR.0000000000000350 Google Scholar

2. 

G. D. Dangas et al., “In-stent restenosis in the drug-eluting stent era,” J. Am. Coll. Cardiol., 56 (23), 1897 –1907 (2010). http://dx.doi.org/10.1016/j.jacc.2010.07.028 Google Scholar

3. 

J. W. Moses et al., “Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery,” N. Engl. J. Med., 349 (14), 1315 –1323 (2003). http://dx.doi.org/10.1056/NEJMoa035071 Google Scholar

4. 

G. W. Stone et al., “Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial,” J. Am. Med. Assoc., 294 (10), 1215 –1223 (2005). http://dx.doi.org/10.1001/jama.294.10.1215 Google Scholar

5. 

M. C. Morice et al., “Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial,” J. Am. Med. Assoc., 295 (8), 895 –904 (2006). http://dx.doi.org/10.1001/jama.295.8.895 Google Scholar

6. 

J. T. Keyes, B. R. Simon and J. P. Vande Geest, “Location-dependent coronary artery diffusive and convective mass transport properties of a lipophilic drug surrogate measured using nonlinear microscopy,” Pharm. Res., 30 (4), 1147 –1160 (2013). http://dx.doi.org/10.1007/s11095-012-0950-y Google Scholar

7. 

J. T. Keyes, B. R. Simon and J. P. Vande Geest, “A finite element study on variations in mass transport in stented porcine coronary arteries based on location in the coronary arterial tree,” J. Biomech. Eng., 135 (6), 61008 –61011 (2013). http://dx.doi.org/10.1115/1.4024137 Google Scholar

8. 

J. T. Keyes et al., “Deformationally dependent fluid transport properties of porcine coronary arteries based on location in the coronary vasculature,” J. Mech. Behav. Biomed. Mater., 17296 –306 (2013). http://dx.doi.org/10.1016/j.jmbbm.2012.10.002 Google Scholar

9. 

A. M. Malek, S. L. Alper and S. Izumo, “Hemodynamic shear stress and its role in atherosclerosis,” J. Am. Med. Assoc., 282 (21), 2035 –2042 (1999). http://dx.doi.org/10.1001/jama.282.21.2035 Google Scholar

10. 

J. D. Talley et al., “Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery. In-hospital and late clinical outcome at 5 years,” Circulation, 82 (4), 1203 –1213 (1990). http://dx.doi.org/10.1161/01.CIR.82.4.1203 Google Scholar

11. 

G. S. Roubin, 3rd S. B. King and Jr. J. S. Douglas, “Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience,” Am. J. Cardiol., 60 (3), 39b –43b (1987). http://dx.doi.org/10.1016/0002-9149(87)90482-6 Google Scholar

12. 

S. L. Chen et al., “Crush stenting with drug-eluting stents: relevance of coronary bifurcation lesion location on angiographic and clinical outcomes,” Clin. Cardiol., 33 (12), E32 –E39 (2010). http://dx.doi.org/10.1002/clc.v33.12 Google Scholar

13. 

S. Elezi et al., “Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents,” J. Am. Coll. Cardiol., 48 (7), 1304 –1309 (2006). http://dx.doi.org/10.1016/j.jacc.2006.05.068 Google Scholar

14. 

J. Daemen et al., “Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study,” Lancet, 369 (9562), 667 –678 (2007). http://dx.doi.org/10.1016/S0140-6736(07)60314-6 Google Scholar

15. 

A. C. Newby and A. B. Zaltsman, “Molecular mechanisms in intimal hyperplasia,” J. Pathol., 190 (3), 300 –309 (2000). http://dx.doi.org/10.1002/(ISSN)1096-9896 Google Scholar

16. 

C. W. Hwang, D. Wu and E. R. Edelman, “Physiological transport forces govern drug distribution for stent-based delivery,” Circulation, 104 (5), 600 –605 (2001). http://dx.doi.org/10.1161/hc3101.092214 Google Scholar

17. 

J Panyam and V. Labhasetwar, “Biodegradable nanoparticles for drug and gene delivery to cells and tissue,” Adv. Drug Deliv. Rev., 55 (3), 329 –347 (2003). http://dx.doi.org/10.1016/S0169-409X(02)00228-4 Google Scholar

18. 

A. Zoumi et al., “Imaging coronary artery microstructure using second-harmonic and two-photon fluorescence microscopy,” Biophys. J., 87 (4), 2778 –2786 (2004). http://dx.doi.org/10.1529/biophysj.104.042887 Google Scholar

19. 

L. G. Montilla, R. Olafsson and R. S. Witte, “Real-time pulse echo and photoacoustic imaging using an ultrasound array and in-line reflective illumination,” Proc. SPIE, 7564 75643C (2010). http://dx.doi.org/10.1117/12.843877 Google Scholar

20. 

L. G. Montilla et al., “Real-time photoacoustic and ultrasound imaging: a simple solution for clinical ultrasound systems with linear arrays,” Phys. Med. Biol., 58 (1), N1 –N12 (2013). http://dx.doi.org/10.1088/0031-9155/58/1/N1 Google Scholar

21. 

American National Standard for the Safe Use of Lasers, American National Standards Institute, New York (2007). Google Scholar

22. 

L. Wang, Biomedical Optics: Principles and Imaging, 362 John Wiley & Sons, Hoboken, New Jersey (2007). Google Scholar

23. 

J. R. Rajian, P. L. Carson and X. Wang, “Quantitative photoacoustic measurement of tissue optical absorption spectrum aided by an optical contrast agent,” Opt. Express, 17 (6), 4879 –4889 (2009). http://dx.doi.org/10.1364/OE.17.004879 Google Scholar

24. 

F. Streit et al., “Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry,” Clin. Chem., 42 (9), 1417 –1425 (1996). Google Scholar

25. 

T. A. Willey et al., “High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma,” J. Chromatogr., 621 (2), 231 –238 (1993). http://dx.doi.org/10.1016/0378-4347(93)80100-I Google Scholar

26. 

D. S. Miller, G. Fricker and J. Drewe, “p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule,” J. Pharmacol. Exp. Ther., 282 (1), 440 –444 (1997). Google Scholar

27. 

V. Daeichin et al., “Frequency analysis of the photoacoustic signal generated by coronary atherosclerotic plaque,” Ultrasound Med. Biol., 42 (8), 2017 –2025 (2016). http://dx.doi.org/10.1016/j.ultrasmedbio.2016.03.015 Google Scholar

28. 

J. L. Su, B. Wang and S. Y. Emelianov, “Photoacoustic imaging of coronary artery stents,” Opt. Express, 17 (22), 19894 –19901 (2009). http://dx.doi.org/10.1364/OE.17.019894 Google Scholar

29. 

A. B. Karpiouk et al., “Feasibility of in vivo intravascular photoacoustic imaging using integrated ultrasound and photoacoustic imaging catheter,” J. Biomed. Opt., 17 (9), 096008 (2012). http://dx.doi.org/10.1117/1.JBO.17.9.096008 Google Scholar

30. 

X. Bai et al., “Intravascular optical-resolution photoacoustic tomography with a 1.1 mm diameter catheter,” PLoS One, 9 (3), e92463 (2014). http://dx.doi.org/10.1371/journal.pone.0092463 Google Scholar

31. 

Y. Li et al., “High-speed intravascular spectroscopic photoacoustic imaging at 1000 A-lines per second with a 0.9-mm diameter catheter,” J. Biomed. Opt., 20 (6), 065006 (2015). http://dx.doi.org/10.1117/1.JBO.20.6.065006 Google Scholar

32. 

B. Wang et al., “In vivo intravascular ultrasound-guided photoacoustic imaging of lipid in plaques using an animal model of atherosclerosis,” Ultrasound Med. Biol., 38 (12), 2098 –2103 (2012). http://dx.doi.org/10.1016/j.ultrasmedbio.2012.08.006 Google Scholar

33. 

X. Li et al., “Intravascular photoacoustic imaging at 35 and 80 MHz,” J. Biomed. Opt., 17 (10), 106005 (2012). http://dx.doi.org/10.1117/1.JBO.17.10.106005 Google Scholar

34. 

Y. Cao et al., “High-sensitivity intravascular photoacoustic imaging of lipid-laden plaque with a collinear catheter design,” Sci. Rep., 6 25236 (2016). http://dx.doi.org/10.1038/srep25236 Google Scholar

35. 

K. Jansen et al., “Photoacoustic imaging of human coronary atherosclerosis in two spectral bands,” Photoacoustics, 2 (1), 12 –20 (2014). http://dx.doi.org/10.1016/j.pacs.2013.11.003 Google Scholar

Biography

Kenneth J. Furdella graduated from Drexel University with a BS degree in biomedical engineering in 2012. He received his master’s in biomedical engineering at the University of Arizona, Tucson, in 2016. While at the University of Arizona, he worked with Jonathan Vande Geest and Russell Witte on photoacoustic imaging. Currently, he is a graduate student in bioengineering at the University of Pittsburgh. He hopes to further his research using photoacoustic imaging to track diffusion coronary arteries.

Russell S. Witte graduated with honors (BS degree in physics, 1993) from the University of Arizona and a PhD (bioengineering, 2002) from Arizona State University. As a postdoctoral fellow, he helped develop new imaging modalities for the brain, heart, and skeletal muscle. He is now associate professor of medical imaging, optical sciences, and biomedical engineering at the University of Arizona. His laboratory devises hybrid imaging and contrast mechanisms that combine light, ultrasound, and/or microwaves to address medical challenges.

Jonathan P. Vande Geest is the principal investigator of the Soft Tissue Biomechanics Laboratory (STBL) and is a professor of bioengineering at the University of Pittsburgh with affiliate faculty appointments in the McGowan Institute for Regenerative Medicine and the Vascular Medicine Institute. The STBL is focused on identifying the structure functions relationships of soft tissues in human pathophysiology using state of the art computational and experimental tools in biomechanics, imaging, and mechanobiology.

© 2017 Society of Photo-Optical Instrumentation Engineers (SPIE) 1083-3668/2017/$25.00 © 2017 SPIE
Kenneth J. Furdella, Russell S. Witte, and Jonathan P. Vande Geest "Tracking delivery of a drug surrogate in the porcine heart using photoacoustic imaging and spectroscopy," Journal of Biomedical Optics 22(4), 041016 (13 February 2017). https://doi.org/10.1117/1.JBO.22.4.041016
Received: 15 September 2016; Accepted: 20 January 2017; Published: 13 February 2017
JOURNAL ARTICLE
7 PAGES


SHARE
Advertisement
Advertisement
Back to Top